CD44 and laryngeal carcinoma: In fact, about 95% of the three laryngeal carcinoma lines in this study (UM-SCC-10B, UM-SCC-15s, and UM-SCC-74B) is overwhelmingly CD44+ underscoring the need for ancillary marker(s) to pinpoint residual cells/TPCs.